Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.
Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?
Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.